Medicofarma Biotech SA
WSE:MDB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.377
1.225
|
Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medicofarma Biotech SA
Net Issuance of Debt
Medicofarma Biotech SA
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Net Issuance of Debt
zł596.7k
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Net Issuance of Debt
-zł105k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Net Issuance of Debt
zł93.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
Selvita SA
WSE:SLV
|
Net Issuance of Debt
-zł38.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Medicofarma Biotech SA
Glance View
Medicofarma Biotech SA is a biotechnology company, which focuses on the innovative medicine, medicinal products, and biotechnology products. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2008-11-27. The company is engaged in works on drugs, medical devices and biotechnological products. It's research and development works are carried out in laboratories in Lublin and Poznan.
See Also
What is Medicofarma Biotech SA's Net Issuance of Debt?
Net Issuance of Debt
596.7k
PLN
Based on the financial report for Dec 31, 2023, Medicofarma Biotech SA's Net Issuance of Debt amounts to 596.7k PLN.
What is Medicofarma Biotech SA's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
37%
Over the last year, the Net Issuance of Debt growth was -13%. The average annual Net Issuance of Debt growth rates for Medicofarma Biotech SA have been 37% over the past three years .